About GDP-fucose protein O-fucosyltransferase 1
GDP-fucose protein O-fucosyltransferase 1 (POFUT1) is a protein
from Homo sapiens identified by UniProt accession
Q9H488, 388 residues long.
MolForge cross-references it against 0 known binders and
106 disease associations.
Target properties
| Protein name | GDP-fucose protein O-fucosyltransferase 1 |
| UniProt accession | Q9H488 |
| Gene | POFUT1 |
| Organism | Homo sapiens |
| Length | 388 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (106)
Diseases linked to this target (Open Targets).
- Dowling-Degos disease · score 0.66
- neurodegenerative disease · score 0.52
- blood protein measurement · score 0.40
- head and neck squamous cell carcinoma · score 0.24
- endometrial cancer · score 0.23
- breast adenocarcinoma · score 0.23
- genetic disorder · score 0.19
- lung adenocarcinoma · score 0.18
- squamous cell lung carcinoma · score 0.18
- alkaline phosphatase measurement · score 0.14
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9H488-F1 | alphafold | PREDICTED | 93.07 | — |
Amino-acid sequence (388 residues)
MGAAAWARPL SVSFLLLLLP LPGMPAGSWD PAGYLLYCPC MGRFGNQADH FLGSLAFAKL LNRTLAVPPW IEYQHHKPPF TNLHVSYQKY FKLEPLQAYH RVISLEDFME KLAPTHWPPE KRVAYCFEVA AQRSPDKKTC PMKEGNPFGP FWDQFHVSFN KSELFTGISF SASYREQWSQ RFSPKEHPVL ALPGAPAQFP VLEEHRPLQK YMVWSDEMVK TGEAQIHAHL VRPYVGIHLR IGSDWKNACA MLKDGTAGSH FMASPQCVGY SRSTAAPLTM TMCLPDLKEI QRAVKLWVRS LDAQSVYVAT DSESYVPELQ QLFKGKVKVV SLKPEVAQVD LYILGQADHF IGNCVSSFTA FVKRERDLQG RPSSFFGMDR PPKLRDEF
Explore GDP-fucose protein O-fucosyltransferase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets